Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Tropical Biomedicine ; : 337-343, 2023.
Artigo em Inglês | WPRIM | ID: wpr-1006848

RESUMO

@#Antibody cross-reactivity among flaviviruses is a major limitation in understanding the prevalence without vector control measures. In this study, we investigated the presence of Zika virus (ZIKV)-specific antibodies and the significance of their cross-reactivity with other flaviviruses, which could affect the serological specificity in both symptomatic and asymptomatic pregnant women. Among the results obtained from 217 serum samples tested for ZIKV-specific IgM and IgG, no specific predictions regarding seropositivity or exposure due to extensive cross-reactivity with dengue virus (DENV) serology could be made. Clear-cut positivity was observed in 1.8% (n = 4) and 1.0% (n = 2) for ZIKV IgM and IgG, respectively. The same samples assessed for DENV showed 1.3% (n = 3) seropositivity each for IgM and IgG levels. None of the samples were positive for ZIKV and DENV IgM or IgG. However, one sample (0.4%) tested positive for ZIKV and DENV IgM. No significant correlation was observed between DENV IgM and IgG when comparing the overlapped serotiters. On the other hand, the ZIKV IgG-positive sample showed higher serotiters for DENV IgG, indicating cross-reactivity with ZIKV but without statistical significance. Therefore, screening for the incidence of ZIKV becomes particularly challenging in a population where the presence or pre-exposure to DENV is observed. Our observations further suggest that unless flavivirus prevalence is properly addressed, determining the prevalence of ZIKV antibodies, which may be confounded with other uninvestigated flaviviruses, will be complicated.

2.
Hepatología ; 2(1): 236-245, 2021. tab, graf
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-1396563

RESUMO

Introducción. La infección por el virus de la hepatitis C (VHC) es un problema de salud pública en el mundo. La Organización Mundial de la Salud (OMS) calcula en más de 70 a 100 millones las personas infectadas. La mayoría de ellas, a lo largo del mundo entero, no han sido diagnosticadas y permanecen sin tratamiento. Objetivo. Determinar la prevalencia de anticuerpos contra el VHC en pacientes con factores de riesgo para la infección, en tres hospitales del departamento de Cundinamarca, Colombia, mediante la prueba rápida SD Bioline en sangre capilar, y la confirmación de la infección por la prueba de ARN-PCR en tiempo real (PCR-RT). Metodología. Estudio de tipo observacional descriptivo donde se incluyeron pacientes adultos atendidos en los servicios de consulta externa de los hospitales de La Mesa, Ubaté y Zipaquirá. Se definieron como factores de riesgo para hepatitis C: antecedente transfusional antes de 1996, cirugías mayores (tórax, abdomen, ortopédicas), tatuajes, piercing. Se empleó como prueba rápida el kit comercial SD Bioline HCV (Standard Diagnostics, INC. Corea). Esta prueba contiene una membrana recubierta con antígenos recombinantes del VHC (core, NS3, NS4, NS5). Resultados. Entre enero y octubre de 2018 se tamizaron 1.856 pacientes, 1.531 mujeres (82%) y 325 (18%) hombres, con edad promedio de 45 años y rango de edad de 18 a 89 años. Los principales factores de riesgo identificados fueron los antecedentes de cirugía y las transfusiones antes de 1996. Se detectaron 2 pacientes mujeres positivas, mayores de 50 años, y como factor de riesgo el haber sido sometidas a cirugía mayor y el antecedente transfusional antes de 1996, confirmadas por la técnica de PCR-RT, lo que da una prevalencia global de la infección del 0,1%, pero del 0,05% en las personas con antecedente quirúrgico, 0,25% entre los mayores de 50 años, y 0,6% en los pacientes con antecedente transfusional antes de 1996. Conclusiones. Este estudio realizado en una población seleccionada por factores de riesgo asociados, mostró una prevalencia global de infección por VHC de 0,1%. Nuestros resultados de tamización con prueba rápida en una población seleccionada con factores de riesgo, sugieren que la estrategia de tamización se debe dirigir a personas mayores de 50 años con antecedente transfusional y cirugía mayor.


Introduction. Infection with hepatitis C virus (HCV) is a worldwide public health problem. The World Health Organization (WHO) estimates that more than 70 to 100 million people are infected. Most of them, throughout the world, have not been diagnosed and remain untreated. Objective. To determine the prevalence of antibodies against HCV in patients with risk factors for infection, in three hospitals in the department of Cundinamarca, Colombia, by means of the rapid SD Bioline test in capillary blood, and the confirmation of infection by real-time PCR (RT-PCR). Methodology. Adult patients treated in the outpatient services of the La Mesa, Ubaté and Zipaquirá hospitals. Risk factors for hepatitis C were defined as: transfusion history before 1996, major surgeries (chest, abdomen, orthopedic), tattoos, and piercing. The commercial SD Bioline HCV kit (Standard Diagnostics, INC. Korea) was used as the rapid test. This kit contains a membrane coated with recombinant HCV antigens (core, NS3, NS4, NS5). Results. Between January and October 2018, 1,856 patients were screened, 1,531 women (82%) and 325 (18%) men, with an average age of 45 years and an age range of 18 to 89 years. The main risk factors identified were a history of surgery and transfusions before 1996. Two positive female patients were detected, older than 50 years, and as a risk factor, having undergone major surgery and a history of transfusion before 1996, confirmed by the RT-PCR assay, which gives a global prevalence of infection of 0.1%, but of 0.05% in people with surgery history, 0.25% among those over 50 years of age, and 0.6% in patients with a transfusion history before 1996. Conclusions. This study, carried out in a population selected for associated risk factors, showed an overall prevalence of HCV infection of 0.1%. Our results suggest that screening with a rapid test in a selected population with risk factors should be directed at people over 50 years of age with a history of transfusion and major surgery.


Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Programas de Rastreamento , Hepatite C , Fatores de Risco
3.
Rev. salud pública ; 20(4): 479-483, jul.-ago. 2018. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-979010

RESUMO

RESUMEN Objetivo Determinar la seroprevalencia de anticuerpos IgG anti-rubéola y anti-citomegalovirus en un grupo de mujeres entre 16 y 40 años, residentes en Tunja. Métodos Investigación descriptiva de corte transversal, en la cual se incluyeron mujeres de 16 a 40 años, por medio de un muestreo no probabilístico por conveniencia. Las variables sociodemográficas fueron registradas mediante encuesta. Se empleó ensayo inmunoenzimático para la determinación cuantitativa de anticuerpos IgG frente a rubéola y citomegalovirus en suero. La estadística aplicada al estudio se llevó a cabo por medio del programa estadístico SPSS versión 21. Resultados El estudio incluyó un total de 154 mujeres en edad fértil, estableciéndose una seropositividad para IgG anti-rubéola de 96,1% (n=148) (IC 95% 93,0 - 99,1) y anti-citomegalovirus de 90,9% (n=140) (IC 95% 86,3 - 95,4). Conclusión Una de cada diez mujeres en estudio está en riesgo de adquirir una infección primaria por citomegalovirus y una de cada 30 por rubéola. El control prenatal por medio de determinaciones serológicas frente a citomegalovirus y rubéola durante el embarazo es primordial en estos casos.(AU)


ABSTRACT Objective To determine the seroprevalence of anti-rubella and anti-cytomegalovirus IgG antibodies in a group of women aged between 16 and 40 years, residents of Tunja. Methods Descriptive, cross-sectional research in women aged between 16 and 40 years included by means of non- probability sampling for convenience. Sociodemographic variables were recorded by applying a survey. An enzyme immunoassay was used for the quantitative determination of rubella and cytomegalovirus IgG antibodies in serum. The statistical analysis was carried out using the statistical program SPSS version 21. Results The study included 154 women of childbearing age, establishing seropositivity for anti-rubella IgG of 96.1% (n=148) (95%CI: 86.3 - 95.4) Conclusion One in ten women included in the study is at risk of primary cytomegalo-virus infection and one in 30 of rubella infection. Prenatal care using serological determinations of cytomegalovirus and rubella during pregnancy is essential in these cases.(AU)


Assuntos
Humanos , Feminino , Gravidez , Diagnóstico Pré-Natal/métodos , Síndrome da Rubéola Congênita/imunologia , Infecções por Citomegalovirus/imunologia , Anticorpos Antivirais , Estudos Soroepidemiológicos , Epidemiologia Descritiva , Estudos de Coortes
4.
Academic Journal of Second Military Medical University ; (12): 37-42, 2014.
Artigo em Chinês | WPRIM | ID: wpr-839058

RESUMO

Objective: To determine the prevalence of human cytomegalovirus (HCMV) infection and plasma level of its neutralizing antibody in hypertension patients, so as to discuss the association between HCMV infection and hypertension. Methods: A total of 51 anti-coagulated blood samples were collected from hypertension patients and the 50 control samples were obtained from age- and sex-matched healthy controls in the Second People's Hospital of Anhui Province from Jan. 2013 to Apr. 2013. Neutralizing antibody level was analyzed by rapid fluorescence micro-neutralization; plasma anti-HCMV IgG and anti-HCMV IgM were determined by enzyme-linked immuno sorbent assay (ELISA), and HCMV UL93 DNA was detected by nested PCR. Results: The positive rates of HCMV UL93 DNA and anti-HCMV IgG in hypertension patients were significantly higher than those in healthy controls (72.55% vs 56.00% for UL93 DNA and 70.59% vs 50.00% for IgG, P0.05). The geometric mean titer of HCMV neutralizing antibody was 38.56 ±20.42 in hypertension patients, which was significantly lower than that in healthy controls (60.12 ± 25.38, P = 0.0326). Conclusion: HCMV positive rate is higher in hypertension patients than in healthy controls; however, the specific neutralizing antibody level of HCMV is greatly lower than that in healthy controls, suggesting that the humoral immune status is declined in hypertension patients and there is a correlation between HCMV infection and hypertension.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA